Koninklijke Philips Plans Annual Dividend of $0.92 (NYSE:PHG)

Koninklijke Philips (NYSE:PHG) announced an annual dividend on Wednesday, May 8th, Wall Street Journal reports. Shareholders of record on Friday, May 10th will be given a dividend of 0.9154 per share by the technology company on Thursday, May 9th. This represents a yield of 3.5%. The ex-dividend date of this dividend is Thursday, May 9th.

Koninklijke Philips Stock Down 1.9 %

Koninklijke Philips stock traded down $0.51 during mid-day trading on Wednesday, hitting $26.00. The company had a trading volume of 1,016,553 shares, compared to its average volume of 1,190,669. The business has a fifty day moving average of $21.35 and a 200 day moving average of $21.33. The company has a quick ratio of 0.78, a current ratio of 1.20 and a debt-to-equity ratio of 0.58. Koninklijke Philips has a 1 year low of $17.75 and a 1 year high of $29.44. The stock has a market cap of $24.14 billion, a price-to-earnings ratio of -27.61, a PEG ratio of 1.39 and a beta of 0.75.

Analyst Upgrades and Downgrades

Several research firms have recently commented on PHG. StockNews.com upgraded shares of Koninklijke Philips from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. BNP Paribas raised Koninklijke Philips from an “underperform” rating to a “neutral” rating in a research note on Tuesday. UBS Group raised Koninklijke Philips from a “sell” rating to a “neutral” rating in a report on Tuesday, April 30th. Finally, JPMorgan Chase & Co. upgraded Koninklijke Philips from an “underweight” rating to a “neutral” rating in a research report on Tuesday, April 30th. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $19.00.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.